1. Show article details.

    More Stringent Testing is Needed as Regions Head for More Lockdowns

    PR Newswire – 9:00 AM ET 11/23/2020

    NEW YORK, Nov. 23, 2020  Biotechnology and pharmaceutical companies are now very close to an effective vaccine to fight the current pandemic. In the meantime, the second wave of the pandemic is hitting harder.

  2. Show article details.

    New Surge of Cases Emphasizes the Need for Widespread Diagnostic Solutions

    PR Newswire – 9:00 AM ET 11/16/2020

    NEW YORK, Nov. 16, 2020 New restrictions are being implemented in several states across the country as the number of those infected with COVID-19 is once again on the rise. While biotech companies work on vaccines and possible treatments and medical device companies focus on patient monitoring, numerous others have been working on improving testing options.

  3. Show article details.

    Vaxart Hosting Key Opinion Leader Panel Call for Investors

    GlobeNewswire – 8:30 AM ET 11/16/2020

    Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics:COVID-19: Immunity & Immunological MemoryNorovirus: Disease Burden & Prevention.

  4. Show article details.

    Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

    GlobeNewswire – 7:00 AM ET 11/16/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast.

  5. Show article details.

    BRIEF-Vaxart Reports Q3 Rev Of $265,000 Versus $454,000

    Reuters – 4:04 PM ET 11/12/2020

    Vaxart Inc (VXRT): * VAXART REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q3 REVENUE $265,000 VERSUS $454,000. * Q3 LOSS PER SHARE $0.08. * Q3 REVENUE ESTIMATE $1.1 MILLION -- REFINITIV IBES DATA. * Q3 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA. * ENROLLMENT IN PHASE 1 FOR ORAL COVID-19 VACCINE TRIAL COMPLETED.

  6. Show article details.

    Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

    GlobeNewswire – 4:01 PM ET 11/12/2020

    Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model Restarting the Norovirus program SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 -- Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today a...

  7. Show article details.

    BRIEF-Vaxart Announces Additional Data From Hamster Challenge Study Of Its Oral Covid-19 Vaccine

    Reuters – 8:17 AM ET 11/12/2020

    Vaxart Inc (VXRT): * VAXART ANNOUNCES ADDITIONAL DATA FROM HAMSTER CHALLENGE STUDY OF ITS ORAL COVID-19 VACCINE. * Vaxart Inc (VXRT) - SIGNIFICANT REDUCTION IN LUNG VIRAL LOAD OF 4-5 LOGS IN HAMSTERS THAT RECEIVED TWO ORAL VACCINE DOSES.

  8. Show article details.

    Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine

    GlobeNewswire – 8:00 AM ET 11/12/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study: As previously announced, all hamsters that received two oral doses of Vaxart’s COVID-19 vaccine candidate showed no systemic weight loss, a key indicator of protection against COVID-19 in this...

  9. Show article details.

    Vaccine Development Holdups Reinforce the Need for Interim Solutions

    PR Newswire – 9:00 AM ET 11/02/2020

    NEW YORK, Nov. 2, 2020 The number of new cases continues to rise, and new restrictions are being implemented. "While it's unfortunate, I don't find it surprising that the timeline is being moved back," said Michael Osterholm, Director of the University of Minnesota's Center for Infectious Diseases Research and Policy.

  10. Show article details.

    VXRT INVESTOR FRAUD 6-DAY DEADLINE: Hagens Berman, National Trial Attorneys, Updates Vaxart (VXRT) Investors: Company Announces Recent Grand Jury Subpoena & SEC Investigation, Hagens Berman Filed Securities Fraud Class Action and Encourages Investors with Significant Losses to Contact the Firm

    GlobeNewswire – 3:18 PM ET 10/17/2020

    Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc. (VXRT) and certain of its senior executives and updates investors.

  11. Show article details.

    BRIEF-Vaxart Reports Positive Hamster Study Data For Oral Covid-19 Vaccine

    Reuters – 8:10 AM ET 10/14/2020

    Vaxart Inc (VXRT): * VAXART ANNOUNCES POSITIVE HAMSTER CHALLENGE STUDY DATA FOR ITS ORAL COVID-19 VACCINE. * Vaxart Inc (VXRT) - AVAILABLE RESULTS SHOW THAT ALL HAMSTERS THAT RECEIVED TWO ORAL DOSES OF COVID-19 VACCINE CANDIDATE SHOWED NO SYSTEMIC WEIGHT LOSS. * Vaxart Inc (VXRT) - ALL ANIMALS VACCINATED WITH TWO DOSES OF ORAL VACCINE MAINTAINED OR GAINED BODY WEIGHT BY END OF EXPERIMENT.

  12. Show article details.

    Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

    GlobeNewswire – 8:00 AM ET 10/14/2020

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today the topline results from its Hamster Challenge Study.

  13. Show article details.

    BRIEF-Vaxart Inc - Entered Open Market Sale Agreement Of Up To $250 Million Of Shares - SEC Filing

    Reuters – 6:00 PM ET 10/13/2020

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - ENTERED OPEN MARKET SALE AGREEMENT OF UP TO $250 MILLION OF SHARES - SEC FILING Source text for Eikon: [ID: https://bit.ly/34U4m35] Further company coverage:

  14. Show article details.

    BRIEF-Vaxart Announces Dosing First Subject In Phase 1 Clinical Trial Of Its Oral Tablet Covid-19 Vaccine

    Reuters – 8:32 AM ET 10/13/2020

    Vaxart Inc (VXRT): * VAXART ANNOUNCES DOSING FIRST SUBJECT IN PHASE 1 CLINICAL TRIAL OF ITS ORAL TABLET COVID-19 VACCINE. * Vaxart Inc (VXRT) - FIRST SUBJECT HAS BEEN DOSED IN ITS PHASE 1 STUDY OF VXA-COV2-1, AN ORAL TABLET COVID-19 VACCINE CANDIDATE Source text for Eikon: Further company coverage:

  15. Show article details.

    Vaxart begins early-stage trial of oral COVID-19 vaccine candidate

    Reuters – 8:13 AM ET 10/13/2020

    Drug developer Vaxart Inc (VXRT) on Tuesday said it has given a dose of its oral COVID-19 vaccine candidate to a participant in an early-stage study. The trial will evaluate two doses of the vaccine candidate, VXA-CoV2-1, in up to 48 healthy volunteers aged between 18 and 54 years old.

  16. Show article details.

    Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

    GlobeNewswire – 8:00 AM ET 10/13/2020

    Open-label, dose ranging study to examine safety and immunogenicity First clinical data readouts in a few weeks Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate.

  17. Show article details.

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates TCMD, VXRT Investors on Firm’s Securities Fraud Class Actions, Reminds of Critical Upcoming Deadlines

    GlobeNewswire – 5:12 PM ET 10/12/2020

    Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. TCMD Investors Click Here.

  18. Show article details.

    VAXART INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vaxart, Inc. - VXRT

    Business Wire – 3:50 PM ET 10/09/2020

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Vaxart, Inc. (VXRT). In early 2020, the Company, which focuses on vaccination research and development, began working on a vaccine for COVID-19.

  19. Show article details.

    Sales Grow as Public Opinion on PPE Shifts

    PR Newswire – 9:00 AM ET 10/07/2020

    NEW YORK, Oct. 7, 2020 The economy shows signs of recovery, but fears that the pandemic will hit with a second wave may cause further devastations in the months to come. In the meantime, the importance and utilization of personal protective equipment by the public has helped prevent even higher numbers of infected.

  20. Show article details.

    BRIEF-Centaur Biopharmaceutical Services Announces Expansion Of Manufacturing Agreement With Vaxart For Covid-19 And Other Vaccine Candidates

    Reuters – 8:19 AM ET 10/07/2020

    Kindred Biosciences Inc (KIN): * CENTAUR BIOPHARMACEUTICAL SERVICES ANNOUNCES EXPANSION OF MANUFACTURING AGREEMENT WITH VAXART FOR COVID-19 AND OTHER VACCINE CANDIDATES. * CENTAUR BIOPHARMACEUTICAL SERVICES - WILL MANUFACTURE VAXART'S ORAL VACCINE FOR COVID-19 AND OTHER VACCINE CANDIDATES.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    12

    VXRT announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.